The 868-page report of the official inquiry into Australia’s Covid-19 response, like the inquiry itself, is not fit for ...
Some health experts say Kennedy, even in an informal role, could potentially lead to real consequences for patients, ...
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age ...
Revelation: Pfizer’s Dangerous Knowledge About COVID-19 Vaccine Risks** New evidence is surfacing that suggests Pfizer was well aware of serious adverse events linked to its C ...
What's more, C. diff is not an easy pathogen to target: Sanofi discontinued its C. diff vaccine candidate in 2017, and a 2024 ...
Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...
Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...
German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...
The Centers for Disease Control and Prevention now recommends that people ages 65 and up and those with weakened immune ...
These dividend stocks could both be wise additions to a long-term investor's portfolio. Pfizer isn't delivering pandemic-era ...
FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback